Wood Sarah M, Lowenthal Elizabeth, Lee Susan, Ratcliffe Sarah J, Dowshen Nadia
1 Craig-Dalsimer Division of Adolescent Medicine, Children's Hospital of Philadelphia , Philadelphia, Pennsylvania.
2 Department of Pediatrics, University of Pennsylvania Perelman School of Medicine , Philadelphia, Pennsylvania.
AIDS Patient Care STDS. 2017 Sep;31(9):377-383. doi: 10.1089/apc.2017.0078.
Youth living with HIV (YLWH) are less likely than older adults to achieve and sustain viral suppression. While treatment guidelines recommend decreased viral load (VL) monitoring in individuals with well-controlled HIV, the appropriateness of this strategy for adolescents is unknown. We conducted a retrospective cohort study to describe longitudinal viral suppression and identify incidence of, and risk factors for, virologic failure among YLWH at a US adolescent HIV clinic from 2002 to 2015. We utilized Cox proportional hazards modeling to compare hazard ratios (HRs) for virologic failure stratified by baseline characteristics. Study participants (n = 365) were predominately African American (87%) and cisgender men and transgender women who have sex with men (80%) and the majority (79%) entered care from 2002 to 2012. Of antiretroviral therapy (ART)-treated participants (n = 201), 88% achieved viral suppression, with 29% subsequently developing virologic failure at a median 12.0 months [interquartile range (IQR) 6.9-22.4] after suppression. The cohort incidence rate of virologic failure was 200 (confidence interval [95% CI]: 151-264) per 1000 person years (PY), with a rate after ≥2 years sustained suppression of 113 (95% CI: 57-227) per 1000 PY. After adjusting for time to ART initiation, initial regimen class, and year of cohort entry, cisgender women had increased hazards of virologic failure (HR 3.2 95% CI: 1.3-7.9, p = 0.01). In conclusion, youth remained at high risk of virologic failure throughout their treatment course, with higher hazards of virologic failure among cisgender women compared with other youth. Maintaining frequent VL monitoring in YLWH may be warranted, even after prolonged viral suppression.
与年长的成年人相比,感染艾滋病毒的青年(YLWH)实现并维持病毒抑制的可能性较小。虽然治疗指南建议减少对艾滋病毒控制良好的个体进行病毒载量(VL)监测,但该策略对青少年的适用性尚不清楚。我们进行了一项回顾性队列研究,以描述美国一家青少年艾滋病毒诊所2002年至2015年期间YLWH的纵向病毒抑制情况,并确定病毒学失败的发生率和危险因素。我们使用Cox比例风险模型来比较按基线特征分层的病毒学失败风险比(HRs)。研究参与者(n = 365)主要是非洲裔美国人(87%),以及与男性发生性关系的顺性别男性和跨性别女性(80%),大多数(79%)于2002年至2012年开始接受治疗。在接受抗逆转录病毒治疗(ART)的参与者(n = 201)中,88%实现了病毒抑制,其中29%在抑制后中位12.0个月[四分位间距(IQR)6.9 - 22.4]出现病毒学失败。病毒学失败的队列发病率为每1000人年(PY)200例(置信区间[95% CI]:151 - 264),在持续抑制≥2年后的发病率为每1000 PY 113例(95% CI:57 - 227)。在调整了开始接受ART的时间、初始治疗方案类别和队列进入年份后,顺性别女性病毒学失败的风险增加(HR 3.2,95% CI:1.3 - 7.9,p = 0.01)。总之,青年在整个治疗过程中仍面临较高的病毒学失败风险,与其他青年相比,顺性别女性病毒学失败的风险更高。即使在长期病毒抑制后,对YLWH进行频繁的VL监测可能也是必要的。